Federated Hermes’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-10,811,153
| Closed | -$230M | – | 2165 |
|
|
2024
Q1 | $230M | Sell |
10,811,153
-75,000
| -0.7% | -$897K | 0.53% | 36 |
|
|
2023
Q4 | $105M | Buy |
10,886,153
+202,364
| +2% | +$983K | 0.26% | 90 |
|
|
2023
Q3 | $27.8M | Buy |
10,683,789
+50,000
| +0.5% | +$160K | 0.07% | 295 |
|
|
2023
Q2 | $49.8M | Buy |
10,633,789
+4,784,689
| +82% | +$20.7M | 0.12% | 209 |
|
|
2023
Q1 | $22.1M | Buy |
5,849,100
+2,625,000
| +81% | +$10.3M | 0.06% | 363 |
|
|
2022
Q4 | $10.2M | Buy |
3,224,100
+50,000
| +2% | +$124K | 0.03% | 534 |
|
|
2022
Q3 | $9.6M | Buy |
3,174,100
+50,000
| +2% | +$125K | 0.03% | 542 |
|
|
2022
Q2 | $7.78M | Buy |
3,124,100
+69,063
| +2% | +$317K | 0.02% | 601 |
|
|
2022
Q1 | $23.7M | Buy |
3,055,037
+1,481,037
| +94% | +$10.7M | 0.05% | 403 |
|
|
2021
Q4 | $6.56M | Buy |
1,574,000
+120,110
| +8% | +$749K | 0.01% | 749 |
|
|
2021
Q3 | $11.5M | Buy |
1,453,890
+856,049
| +143% | +$7.21M | 0.02% | 610 |
|
|
2021
Q2 | $4.83M | Buy |
597,841
+32,841
| +6% | +$283K | 0.01% | 846 |
|
|
2021
Q1 | $6.06M | Buy |
565,000
+40,000
| +8% | +$468K | 0.01% | 790 |
|
|
2020
Q4 | $6.17M | Buy |
525,000
+15,000
| +3% | +$188K | 0.01% | 754 |
|
|
2020
Q3 | $6.13M | Buy |
510,000
+190,000
| +59% | +$2.6M | 0.01% | 689 |
|
|
2020
Q2 | $5.59M | Buy |
+320,000
| New | +$5.57M | 0.01% | 685 |
|
Federated Hermes's FUSN Position: Q2 2024 in Review
Federated Hermes sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q2 2024, closing a stake of 10,811,153 shares — an estimated $230M sold.
Federated Hermes first reported a position in FUSN in Q2 2020 and held it in 16 quarters. The position peaked at $230M in Q1 2024. 0 funds tracked by Wall St. Rank hold FUSN as of Q2 2024.
- Federated Hermes reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q2 2024 after selling out during the quarter.
- Federated Hermes sold 10,811,153 Fusion Pharmaceuticals Inc. Common Shares shares in Q2 2024, an estimated $230M.
- Federated Hermes first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q2 2020 and held it in 16 quarters.
- Federated Hermes's Fusion Pharmaceuticals Inc. Common Shares position peaked at $230M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q2 2024.
Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.